UAE drug-control push puts AED 50,000 pharmacy penalties back in focus

UAE Public Prosecution used a 28 September 2026 panel at the 15th United Nations Congress on Crime Prevention and Criminal Justice in Abu Dhabi to frame drug control as a health-system issue as well as a criminal-justice priority.

The highest-stakes readers are pharmacy operators, clinic COOs and medical directors. The message affects how controlled medicines are prescribed, dispensed, documented and referred for treatment across Dubai, Abu Dhabi and the northern emirates. It also matters to insurers handling claims where controlled medicines, addiction care or psychiatric pathways appear in the episode of care.

What prosecutors said in Abu Dhabi

Dr. Saeed Al Ahbabi, a prosecutor at the Federal Drug Prosecution, made the remarks during a panel organised by the National Anti-Narcotics Authority on the sidelines of the congress, according to Emirates News Agency. The congress runs at ADNEC Centre Abu Dhabi from 26 September to 1 October 2026.

The UAE approach combines prevention, awareness and treatment with supply reduction and law enforcement to strengthen public safety. Dr. Saeed Al Ahbabi, Federal Drug Prosecution

The Ministry of Justice said before the congress that expected participation was 3,000 to 5,000 people from more than 97 countries, with the Abu Dhabi Declaration intended to guide five years of crime-prevention and criminal-justice work. For healthcare operators, the relevant signal is narrower. Enforcement policy is being discussed beside treatment, prevention and demand-reduction policy.

Why clinics and pharmacies should care

In Dubai, the operational regulator is the Dubai Health Authority (DHA). In Abu Dhabi and Al Ain, it is the Department of Health Abu Dhabi (DOH). In Sharjah, Ajman, Ras Al Khaimah, Fujairah and Umm Al Quwain, the main health regulator is the Ministry of Health and Prevention (MOHAP). Medical-product regulation now also involves the Emirates Drug Establishment, after federal amendments shifted relevant references from MOHAP to EDE.

The compliance risk is concrete. UAE legislation published in December 2025 says a pharmacy that dispenses narcotic drugs or psychotropic substances without a valid prescription, or above approved limits, faces imprisonment of at least five years and a fine of at least AED 50,000. The same minimum prison term and fine apply to a physician who issues a controlled-drug prescription without a licence, without medical justification or outside approved limits.

Operators should treat the public-prosecution statement as a reminder to test four controls before the next inspection or payer audit:

• Prescriber licence status in the relevant emirate, checked against DHA, DOH or MOHAP systems.
• Controlled-medicine prescription forms, duration limits and refill rules, checked against current emirate and federal guidance.
• Pharmacy stock, dispensing and destruction logs, reconciled to invoice and prescription records.
• Referral routes for suspected substance-use disorder, including emergency, psychiatric and rehabilitation pathways.

Abu Dhabi has stricter documented pathways for narcotic and psychotropic medicines. The UAE Government portal says narcotics in Abu Dhabi may be prescribed only by a HAAD-licensed physician for an inpatient on the approved narcotic prescription form, while outpatient psychotropic prescriptions carry special requirements. Operators should verify the current DOH successor rules rather than relying on old internal pharmacy manuals.

Insurer and patient implications

For payers, the immediate P&L issue is avoidable rejection and leakage. Insurers such as Daman and Thiqa in Abu Dhabi, and commercial payers such as Sukoon where they are on the policy, can require prior authorisation, formulary checks and clinical documentation before reimbursing high-risk medicines or related psychiatric care. Clinics should confirm the current tariff, CPT mapping and pre-approval status inside the payer portal. If the number is unavailable there, it should be requested in writing from the insurer before the drug is dispensed.

For patients, the practical issue is access without legal exposure. The UAE Government portal states that recreational drugs are banned and that controlled medicines are restricted. It also says patients may need MOHAP permission to import certain medicines for personal use. Travellers and residents using opioids, stimulants, benzodiazepines or other restricted medicines should keep the prescription, diagnosis and import permit where required before arrival or dispensing.

Dubai operators face the largest retail-pharmacy market in the country. The UAE Open Healthcare Directory lists 1,680 DHA-licensed pharmacies in Dubai. That density raises the audit burden for chains and single-site pharmacies alike, because a controlled-medicine failure can sit with the pharmacist, the medical director and the facility owner.

The next watch point is whether DHA, DOH, MOHAP or EDE issue follow-up circulars after the Abu Dhabi congress. Pharmacy owners should assign one accountable person to monitor circulars weekly through regulator portals and payer bulletins. Patients and referral teams looking for licensed pharmacy providers can start with the UAE Open Healthcare Directory.